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The spectrum of primary immunodeficiencies
at a tertiary care hospital in Pakistan
Sonia Qureshia, Fatima Mira, Samina Junejob, Khalid Saleemc, Samreen Zaidid, Abdullah B. Naveede,
Khalil Ahmada and Farah Naz Qamara*
ABSTRACT
Background: Primary Immunodeficiency Disorders (PIDs) are well-known disorders in the West.
but the recognition and diagnosis of these disorders is challenging in developing countries. We
present the spectrum of PIDs seen at a tertiary care center in Pakistan, identified using clinical case
definitions and molecular methods.
Methods: A retrospective chart review of children suspected to have PID was conducted at the
Aga Khan University Hospital (AKUH) Karachi, Pakistan from 2010 to 2016. Data on demographics,
clinical features, family history of consanguinity, sibling death, details of laboratory workup done
for PID and molecular tests targeted panel next generation sequencing (NGS) or whole exome
sequencing (WES) performed at the Geha laboratory at Boston Children’s Hospital, USA was
collected. The study was exempted from the Ethical Review Committee of AKUH.
Results: A total of 43 children visited the hospital with suspected PID during the study period.
Genetic testing was performed in 31/43 (72.1%) children. A confirmed diagnosis of PID was
established in 20/43 (46.5%) children. A pathogenic gene variant was identified in 17(85%) of the
20 confirmed cases (Table 1). Twelve (60%) of the confirmed cases of PID were male. The most
common presenting symptom was recurrent diarrhea 11/20 (55%). The mean (S.D) age of the
cases at the time of diagnosis was 4.2 (4.1) years. Chronic granulomatous disease (CGD) was the
most common 6/20 (30%) disorder, followed by severe combined immunodeficiency (SCID) 3/20
(15%), leukocyte adhesion deficiency (LAD) 3/20 (15%), agammaglobulinemia/hypogamma-
globulinemia 3/20 (15%), and Hermansky-Pudlak Syndrome (HPS) 2/20 (10%). Wiskott-Aldrich
Syndrome, Immunodeficiency Centromeric Instability and Facial Anomalies Syndrome (ICF 2),
Trichohepatoenteric syndrome (TRES), and C3 deficiency were each diagnosed once {1/20 (4.3%)
each} (Table 1). Of these 20 confirmed cases, almost all 19/20 (95%) had a family history of
consanguinity. Sibling death was reported in 5/20 (25%) of these cases. Five out of the 20 (25%)
children died over the 7-year period for various reasons.
Conclusion: PIDsarenotuncommon inPakistan; theirdiagnosismaybemissedordelayeddue to the
overlapping of clinical features of PID with other diseases and a lack of diagnostic facilities. There is a
need to build capacity for early recognition and diagnosis of PIDs to decreasemorbidity andmortality.
Keywords: Children, Primary immunodeficiency disorders, Chronic granulomatous disease,
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INTRODUCTION
Primary immunodeficiency disorders (PIDs) are
a heterogeneous group of genetic disorders
characterized by an impaired ability of the immune
system to produce a normal immune response.
This is due to inherited defects in either cellular or
humoral immunity, which results in a spectrum of
issues such as recurrent infections, allergies,
autoimmunity, and malignancies.1,2 In neonates,
PIDs often present with severe infections leading
to death; whereas in adolescents these infections
are less severe albeit recurrent. Diagnosing PIDs
is challenging because of the variability in clinical
presentation and limited availability of diagnostic
tests, particularly in low middle-income countries
(LMIC). When diagnostic tests are available, their
cost often becomes a limiting factor. Advances in
molecular diagnostic techniques and the identifi-
cation of known gene defects have helped to
facilitate the diagnosis of patients with PIDs.3 The
true global prevalence and distribution of PIDs
remain unclear. The prevalence statistics available
from nationwide registries are mostly derived
from limited areas of the world. The data
obtained from these registries often
underestimate the true prevalence, because not
all cases are reported to these registries, and due
to ambiguity in what constitutes a PID case, some
cases are missed. These issues are compounded
in developing countries because of the lack of
physician training in identification of these
disorders and the limited access to diagnostics in
these countries. Recent studies have shown that
PIDs are more common than previously thought,
and that around 1% of the population may have
an underlying PID.4 The burden of PID varies by
region, being highest in the United States of
America (USA), followed by Europe, Latin
America, Middle East, Asia, and finally Africa.4
This frequency may be biased by the availability
of resources for diagnosis of these disorders.
Most PIDs are autosomal recessive, which makes
it safe to assume that the incidence of PIDs is
greater in regions having higher rates of consan-
guinity. However, limited studies have been car-
ried out in such regions and hence the burden and
type of PIDs in such areas is relatively unknown.
Consanguineous marriages are common in
developing Asian countries ranging between 20
and 70% of all marriages, and Pakistan is no
different, with about 70% of the marriages being
consanguineous.5–7 The data on PIDs in Pakistan is
currently confined to a few case reports, case
series, and editorials; there are no detailed
reports on the spectrum of PIDs seen in the
country.8–11
Diagnosing and treating PIDs is a challenge in
Pakistan. Patients often die before the disorder is
recognized by a physician, leading to a delay in
diagnosis or death of the child. Families are often
referred to tertiary care centers following the death
of a sibling or for admission for life-threatening
infections. Even in large tertiary care centers with
well-equipped laboratories, there are limited
diagnostic facilities available for confirming PIDs.
Even when these are available, the diagnostic tests
are expensive and beyond the reach of most
families as the health care system of Pakistan relies
on out-of-pocket payments for health expendi-
tures. Once the diagnosis of PID is confirmed,
supportive therapies like antibiotic and antifungal
prophylaxis, intravenous (I/V), or subcutaneous (S/
C) immunoglobulin therapy, depending on the
underlying disorder, are offered. Intravenous
immunoglobulin (IVIG) is the standard therapy for
most humoral deficiencies, but it is expensive and
beyond the reach of most patients in low middle
income countries (LMICs). S/C immunoglobulins
provide ease of administration, but their availabil-
ity is limited in LMICs. Bone marrow transplant is
available in certain settings but has its limitations in
countries like Pakistan where no donor registries
are available, and the cost of the transplant
coupled with the risk of infections in the post-
transplant period make this option challenging to
pursue. Gene therapy is another promising albeit
costly treatment option undergoing experimenta-
tion and is now considered an option for the
treatment of multiple non-life-threatening disor-
ders (ie, immunological disorders and systemic
protein deficiency). This study aims to report the
spectrum of PID cases observed at a tertiary care
center in Pakistan, with a focus on the molecular
diagnosis in this patient population over the last 7
years.
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MATERIALS AND METHODS
The Aga Khan University Hospital (AKUH) is a
700 bed, not-for-profit tertiary care hospital in
Karachi, Pakistan. The hospital receives referrals
from all over the country. A retrospective chart
review of children suspected to have PID was
conducted at the AKUH, Pakistan from 2010 to
2016. Data on demographics, clinical features, age
at onset of symptoms, age at presentation, history
of recurrent infections, skin allergies, family history
of consanguinity, sibling death, details related to
laboratory workup done for PID (complete blood
count, serum immunoglobulin levels, nitro-
tetrazolium blue test (NBT), dihydro-
rhodamine(DHR) and flow cytometric analysis)
were collected. Molecular tests targeted panel
next generation sequencing (NGS) or whole
exome sequencing (WES) were performed at Geha
laboratory at Boston Children’s Hospital, USA.
Targeted panel NGS was performed using the PID
v2 panel and Ion Torrent S5 sequencer (Ther-
moFisher), with an average coverage of 328x.
Variant annotation was performed with VarSeq
software (Golden Helix). Whole exome sequencing
(WES) was performed using a previously described
pipeline with an average on-target coverage of
80.12 The cost of shipping and molecular testing
was covered by a philanthropic grant from the
Perkins Fund. Data were analyzed using IBM
SPSS Statistics v. 20.0. Mean  S.D is reported for
quantitative variable like age at diagnosis, delay
in diagnosis (days), etc. Frequency and
percentages are reported for categorical
variables such as gender, type of PID, clinical
features, history of sibling death, consanguinity in
family, mortality, etc.
RESULTS
A total of 43 children visited the hospital with a
suspected PID during the study period. Among
them, genetic testing was performed in 31/43
(72.1%) children. A confirmed diagnosis was
established in 20/43 (46.5%) children. A patho-
genic gene variant was identified in 17 (85%) of the
20 confirmed cases (Table 1). Of the remaining 23
patients, samples for 9 patients were not sent for
molecular testing, 7 had no known genetic
mutation for PID (Table 2), no pathogenic genetic
variant was identified in 2 patients, 2 died before
a final diagnosis could be established, 2 were
lost to follow-up, and 1 had normal sequencing
results (Fig. 1). Twelve (60%) of the 20 confirmed
children with PID were male. The mean (S.D)
age at the time of diagnosis was 4.2 (4.1) years.
The mean (S.D) delay in diagnosis was
1333  1420 days. The most common presenting
symptom was recurrent diarrhea 11/20 (55%)
followed by recurrent pneumonia 8/20 (40%),
oral thrush 7/20 (35%), skin rashes and abscesses
6/20 (30%), osteomyelitis 1/20 (5%), and
meningitis 1/20 (5%). Chronic granulomatous
disease (CGD) was the most common 6/20 (30%)
disorder, followed by severe combined
immunodeficiency (SCID) 3/20 (15%), leukocyte
adhesion deficiency (LAD) 3/20 (15%),
agammaglobulinemia/hypogammaglobulinemia
3/20 (15%), and Hermansky-Pudlak Syndrome
(HPS) 2/20 (10%). Wiskott-Aldrich Syndrome, Im-
munodeficiency Centromeric Instability and Facial
Anomalies Syndrome (ICF 2), Trichohepatoenteric
syndrome (TRES), and C3 deficiency were each
diagnosed once {1/20 (4.3%) each} (Table 1). Of
these 20 confirmed cases, almost all 19/20 (95%)
had a family history of consanguinity. Sibling
death was reported in 5/20 (25%) of these cases.
Five out of 20 (25%) children died due to various
reasons. A pathogen (Pneumocystis jiroveci) was
identified in only 1 of the 5 deceased patients.
Among the deceased children, 2 developed
acute respiratory distress syndrome (ARDS), 2
died of sepsis, and 1 had plastic bronchitis.
DISCUSSION
In this case series, 85% of the children were able
to get a molecular diagnosis through the support
of Boston Children’s Hospital. CGD was the com-
monest disorder observed. This is consistent with
data reported from other Asian countries in which
phagocytic defects were the most common type of
PIDs ranging from 29% to 60%.13–15 Almost all
cases in this study had a family history of
consanguinity. Death of siblings was seen in 25%
of the cases. Out of the children who died during
the study period, 80% of them were diagnosed
after they had died.
Due to a lack of facilities, diagnosing PIDs con-
tinues to be a challenge in developing countries.
Partnering with international organizations is
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S.No Age/Sex
Clinical
Features
Consan
guinity
Sibling
Death
(Age/
Cause of
death)
aSpecial
Investigations
(Normal range)
Mutated
Gene
Final Diag
nosis
Age at
onset of
sym
ptom
Age at
diag
nosis
Out
come
Phagocyte Defects (n ¼ 9)
1 11 mo/M Recurrent abscesses
and osteomyelitis
Yes Yes (18 mo old
brother & 16 days
old brother with
no apparent
cause)
NBT: Negative
DHR: Positive
Immunoglobulins
IgG:15.2 (6.5–16)
IgA: 3.68 (0.4–3.5)
IgM:1.15 (0.5–3.0)
IgE: not done
Flow cytometry
Not done
HIV-serology: not done
Gene
NCF1
Loss of
coverage
Exon 2 could
not be
amplified,
suggesting a
deletion that
includes this
exon
AR CGD Birth 6 yr Alive
2 3.3 yr/M Recurrent abscesses,
lymphad enopathy
No Yes (9 mo old
brother due to
pneumonia)
NBT: Negative
DHR: Not done
Immunoglobulins
IgG:23.1 (5.7–17.1)
IgA: 3.58 (0.47–2.5)
IgM:2.38 (0.64–2.7)
IgE: not done
Flow Cytometry
CD3: 5203 (1500–2900)
CD4: 2328 (1000–2100)
CD8: 1999 (700–1100)
CD19: 2407(500–1200)
CD 56: 556 (300–600)
HIV-serology:Negative
Gene
CYBB
Zygosity
Homozygous
Genomic
coordinate
c.1222G > A
Amino acid
Change
p.Gly408Arg
X-linked CGD 9 mo 8 yr 9 mo Alive
3 3 mo/M Recurrent diarrhea,
perianal abscess, skin
rash
Yes No NBT: Negative
DHR: Not done
Immunoglobulins
IgA: 0.2 (0.09–1.07)
Others: not done
Flow Cytometry
CD3: 1652(1800–3300)
CD4: 1224 (900–2300)
CD8: 237 (700–1500)
CD19: 839(700–1700)
CD 56: not done
HIV status: not checked
Gene
NCF1
Zygosity
Homozygous
Genomic
coordinate
c.294_
295insA
Amino acid
change
p.Gly99fs
AR CGD 2 mo 2 yr
9 mo
Alive
4 1.3 yr/F Recurrent
diarrhea, cow
milk protein
allergy
Yes Yes (1.5 years old
sister due to septic
shock & had
similar complaints,
no workup done
for PID)
NBT: Absent activity
DHR: Not done
Immunoglobulins
IgG:13.4 (6.5–16.0)
IgA:2.49 (0.4–3.5)
IgM:1.14 (0.5–3.0)
IgE: 1336 (0.4–351.6)
Flow cytometry
CD3: 5030 (1900–2900)
CD4: 3617 (1000–1800)
CD8: 1388 (700–1200)
CD19: 5073(600–1400)
CD56:1279 (300–600)
HIV status: not checked
Gene
NCF2
Zygosity
Homozygous
Genomic
coordinate
Chr1:
183532647
Loss of
coverage:
1098_
1099delTC
¼ p.Gln367fs
(Frameshift
deletion)
AR CGD Birth 2 yr Alive
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5 3 yr/M Recurrent
pneumonias, oral
thrush, perianal
abscess
lymphadenopathy
Yes No NBT: Normal
DHR: Not done
Immunoglobulins
IgG: 7.62 (.05–14.0)
IgA:1.56((0.18–1.7))
IgM: 1.20(0.63–2.9)
IgE: >2000(0.4–351.6)
Flow cytometry
CD3: 6124(1500–2900)
CD4: 3355(1000–2100)
CD8: 2539(700–1100)
CD19:1830(500–1200)
CD56:not done
HIV serology: Negative
Gene
NCF1
Zygosity
Homozygous
Genomic
coordinate
Chr7:
74191664
Amino acid
change
p.Arg42Trp
AR CGD 2 yr 4 yr
5 mo
Alive
6. 7 yr/M Recurrent pneumonia Yes No NBT: Not done
DHR: Positive
Immunoglobulins
Not done
Flow cytometry
Not done
HIV status: not checked
Not done CGD 9 mo 7 yr Alive
7. 3.5 mo/F Delayed shedding of
umbilical cord,
recurrent oral thrush,
skin rash,
Yes No Immunoglobulins
Not done
Flow cytometry
Not done
HIV status: not checked
Gene
FERMT3
Zygosity
Homozygous
Loss of
coverage
(Kindlin-3)
c.126_
126delC ¼
p.Ile42fs
(Frameshift
deletion)
LAD3 2 mo 1yr 4 mo Alive
8. 7 mo/F Delayed shedding of
umbilical cord,
recurrent diarrhea,
skin rash
Yes No Immunoglobulins
IgG:4.02
(6.5–16)
IgM:1.36
(0.5–3.0)
IgA: 0.36 (0.4–3.5)
IgE: 31.0 (1.4–52.3)
Flow Cytometry
CD3: 3987 (2800–3500)
CD4: 3122 (1700–2400)
CD8: 784 (800–1100)
CD 56: 444 j(300–800)
CD19: 2168 (1000–1700)
HIV status: not checked
Gene
ITGB2
Zygosity:
Homozygous
Genomic
coordinate
(GRCh37/
hg19): c.134G
> A
Amino acid
change
p.Trp45Ter
(Nonsense)
LAD1 12 days 5 mo Alive
9. 4 mo/M Delayed shedding of
umbilical cord and
umbilical abscess
Yes No cFlow cytometry for LAD
markers:
CD11C deficiency
Not done LAD2 Birth 3 mo Alive
Combined/Cellular defects (n ¼ 7)
10. 4 mo/M Recurrent diarrhea,
skin rash
Yes No Immunoglobulins
IgG: <0.7 (6.5–16.0)
IgA: <0.15 (0.4–3.5)
IgM: 0.0 (0.5–3.0)
IgE: 440 (1.4–52.3)
Flow Cytometry
Gene
RAG2
Zygosity
Homozygous
Genomic
coordinate
SCID Omenn
syndrome
1.5 mo 5 mo Alive
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CD3: 150 (1800–3300)
CD4: 150 (900–2300)
CD8: 1 (700–1500)
CD56:108 (300–800)
CD19: 0 (700–1700)
HIV status: not checked
c.1247G > T
Amino acid
change
p.Trp416Leu
11. 5 mo/F Recurrent
pneumonia,
diarrhea, otitis
media, skin
rash
Yes No Immuno
globulins
IgG:0.66
(1.9–7.9)
IgA: <0.15
(0.01–0.59)
IgM: not done
IgE: 18 (1.4–52.3)
Flow Cytometry
CD3: 428 (2800–3500)
CD4: 283 (1700–2400)
CD8: 122 (800–1100)
CD56: not done
CD19: 25(1000–1700)
HIV serology: Negative
Gene
RAG1
Zygosity
Homozygous
Genomic
coordinate
Chr 11:
36597688_
A >
T ¼ c. 2834
A > T
Amino acid
change
p.H945L
SIFT (0.01);
Polyphen
(0.969).
SCID 3 mo 6mo Died due to
bARDS and
bPCP
pneumonia
(1 month
before
establishing
diagnosis)
12. 1 yr/F Recurrent diarrhea,
oral thrush
Yes No Immunoglobulins
Ig G: 0.83 (not available)
IgA: 0.17 (not available)
IgM: 0.23 (not available)
IgE: not done
Flow cytometry
CD3: 32 (not available)
CD4: 6 (not available)
CD8: 23 (not available)
CD19: 397 (not available)
HIV serology: Negative
Gene
JAK3
Amino acid
change
p.P402L.
SIFT (0).
Polyphen
(0.85)
SCID 8 mo 1 yr 2 mo Died due to
bARDS
(2 months
before
establishing
diagnosis)
13 2.5 yr/M Oral thrush, skin rash,
Food allergy, anemia,
thrombocytopenia
Yes No Immunoglobulins
Ig G:19.4 (not available)
Ig A: 2.99(not available)
Ig M: 0.76(not available)
Ig E: >5000(not available)
Flow Cytometry
CD3: 1126(not available)
CD4: 285(not available)
CD8: 675(not available)
CD19: 75(not available)
CD56: 299(not available)
HIV status: not checked
Gene
WAS
Zygosity
Hemizygous
Genomic
coordinate
ChrX:
48543941
(Deletion of C)
Arg94fs
(Frameshift
deletion)
WAS 9 mo 3 yr 1 mo Died due to
sepsis
(5 months
before
establishing
diagnosis)
14. 9 mo/F Recurrent diarrhea,
pneumonia, oral and
perianal candidiasis
Yes No Immunoglobulins
IgG: 4.6 (6.5–16)
IgA: <0.33 (0.4–3.5)
IgM: 0.21 (0.5–3.0)
Ig E: 1.23 (1.4–52.3)
Flow cytometry
Gene
ZBTB24
Zygosity
Homozygous
Genomic
coordinate
ICF 2 4 mo 1 yr 10 mo Died due to
Plastic
bronchitis.
(2.5 months
after
diagnosis)
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CD3: 4286 (1900–2900)
CD4: 2942 (1000–1800)
CD8: 824 (700–1200)
CD56: 331 (300–600)
CD19: 944 (600–1400)
HIV status: not checked
Chr6:
109802832
c.396_
397delTA
¼ p.His132fs
(Frameshift
deletion)
15 6 yr/M Recurrent diarrhea,
pneumonia, occulo-
cutaneous albinism,
blond hairs, easy
bruisibility, oral thursh
Yes No Immunoglobulins
Ig G: 9.7 (6.5–16)
Ig A: 4.0 (0.4–3.5)
IgM: 0.28 (0.5–3.0)
IgE: 28 (0.5–393)
Flow cytometry
Not done
HIV status: not checked
No
pathogenic
variant found
(Diagnosed on
the basis of
clinical
findings and
family history
of similar
illness in his
first cousin)
Hermansky-
Pudlack syndrome
Birth 7 yr Alive
16. 16 y/F Recurrent diarrhea,
pneumonia, occulo-
cutaneous albinism,
blond hairs, easy
bruisibility, oral thrush,
epistaxis, otitis media
Yes Yes (2.5 years old
brother due to
pneumonia & had
similar features
and complaints)
Immunoglobulins
Ig G:17.8 (6.5–16)
Ig A: 4.48 (0.4–3.5)
IgM: 0.45 (0.5–3.0)
IgE: 12.0 (1.9–170)
Flow cytometry
CD3:1330 (720–2320)
CD4: 592 (430–1010)
CD8: 687 (170–1050)
CD19:175 (100–430)
CD56: 48 (100–430)
HIV serology:Negative
Not done
(Diagnosed on
the basis of
clinical
findings and
family history
of similar
illness in her
first cousin)
Hermansky-
Pudlack syndrome
1 yr 17 yr Alive
Humoral/Antibody defects (n ¼ 3)
17. 3 yr/M Recurrent diarrhea
Recurrent abscesses
Yes No Immunoglobulins
IgG: <0.7 (5.7–17.1)
IgM: <0.08 (0.64–2.7)
IgA: <0.15 (0.47–2.5)
IgE: 51 (0.4–351.6)
Flow cytometry
CD3: 1444 (1500–2900)
CD4: 389 (1000–2100)
CD8: 1064 (700–1100)
CD19: 2 (500–1200)
CD56: 165 (300–600)
HIV serology: Negative
Gene
BTK
Loss of
coverage
frameshift
deletion
resulting in
exon18 ¼
c.1883delC ¼
p.T628fs
X-linked Agamma-
globulinemia
2yr 4yr 9 mo Died due to
sepsis
(4 months
before
establishing
diagnosis)
18. 8 yr/F Recurrent diarrhea and
pneumonia
Yes No Immunoglobulins
IgG:1.11(7.3–15.1)
IgM: 0.14(0.55–2.1)
IgA: <0.15 (0.7–3.25)
IgE: <0.1 (0.5–393)
Flow cytometry
CD3: 3472(1300–2200)
CD4: 1513 (600–1100)
CD8: 1787(500–1000)
CD19: 49(300–500)
CD56:176(300–500)
HIV status: not checked
Gene
TCF3
Zygosity
Homozygous
Loss of
coverage
Total loss of
coverage of
exons 5–11.
Agamma
globulinemia
1 yr 8 yr 7 mo Alive
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19. 1.9 yr/M Recurrent pneumonia Yes Yes (5 years old
brother due to
measles)
Immunoglobulins:
IgG: 9.64 (6.5–16.0)
IgM: 0.6 (0.5–3.0)
IgA: 0.69 (0.4–3.5)
IgE: 3.37 (0.4–351.6)
Flow cytometry:
CD3:1653 (1500–2900)
CD4:1242 (1000–2100)
CD8: 427 (700–1100)
CD19: 12 (500–1200)
CD56: 132 (300–600)
HIV status: not checked
Gene
TTC37
Zygosity
Homozygous
Genomic
coordinates
(GRCh37/
hg19):
c.1864A > C
Amino acid
change
p.Thr622Pro
Polyphen:
0.89
SIFT: 0.41
Trichohe
patoenteric
syndrome (THES)
Birth 1 yr 10 mo Alive
Complement Deficiency (n ¼ 1)
20. 4.5 yr/M Recurrent meningitis Yes No Complement Level
C3: 0.05 g/L(0.8–1.5)
Gene
C3
Zygosity
Homozygous
Genomic
coordinates
(GRCh37/
hg19): Chr19:
6711208 C >
A (50
Splicesite,
Exon 12)
C3 deficiency 1 yr 5 yr Alive
Table 1. (Continued) Clinical and Laboratory characteristics of patients with a confirmed Primary immunodeficiency disorder. a. CD count unit: cells/mm3,Immunoglobulin unit: G/L, IgE unit: IU/ml,
NBT: Nitrotetrazolium blue test, DHR: Dihydrorhodamine. b. ARDS: Acute Respiratory Distress Syndrome, PCP: Pneumocystis carini c. Sample sent to Armed Forces of Institute of Pathology (AFIP), Rawalpindi to check
the CD markers for Leukocyte Adhesion Defect (LAD) on flow cytometry
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S.No Age/Sex ClinicalFeatures
aSpecial Investigations
(Normal range)
Suspected
diagnosis
Gene
Sequence
Result
Age at onset
of symptom
Age at
diagnosis Outcome
1 10 mo/M Recurrent
diarrhea
Immunoglobulins
IgG:<0.7 (1.9–7.9)
IgA:<0.15 (0.01–0.59)
IgM:<0.08 (0.09–2.1)
IgE:1.0 (1.4–52.3)
Flow cytometry
CD3:166(1800–3300)
CD4:132(900–2300)
CD8: 27 (700–1500)
CD19: 22(700–1700)
CD56: 530(300–800)
HIV serology: negative
TBþNKSCID No Known
candidate gene
for PID
identified
Birth 10 mo. Died due to
sepsis
2 2.5 yr/M Work up was
done because
of family history
of SCID.
Immunoglobulins
Not done
Flow cytometry
CD3:503(1500–2900)
CD4: 451(1000–2100)
CD8: 68(700–1100)
CD19:12(500–1200)
CD56: not done
HIV status: not checked
TB-NK- SCID No Known
candidate gene
for PID
identified
10th day of life 1 yr 8 mo. Died due to
sepsis
3 6 mo/M Fever, leg
gangrene,
seizures
Immunoglobulins
IgG:10.7(6.5–16)
IgA: 0.31(0.4–3.5)
IgM:0.2(0.5–3)
IgE:12.4(1.4–52.3)
Flow Cytometry
CD3:1140(1800–3300)
CD4:735(900–2300)
CD8: 449(700–1500)
CD56: 49 (300–800)
CD19: 273(700–1700)
HIV serology: negative
SCID No Known
candidate gene
for PID
identified
1.5 mo. 4 mo. Alive
No
recurrence of
infections in
follow up.
Less likely to
be a PID
4 13 yr/M Recurrent
diarrhea and
joint swelling
Immunoglobulins
IgG: 1.11(5.7–17.1)
IgA: 0.41(0.47–2.5)
IgM: 0.05(0.64–2.7)
IgE: 2.85(1.9–170)
Flow Cytometry
CD3:1718(1100–2200)
CD4: 651(600–1600)
No No Known
candidate gene
for PID
identified
6 yr. 13 yr. Alive
(continued)
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S.No Age/Sex ClinicalFeatures
aSpecial Investigations
(Normal range)
Suspected
diagnosis
Gene
Sequence
Result
Age at onset
of symptom
Age at
diagnosis Outcome
CD8: 850(500–1200)
CD19: 454(200–600)
CD56: 83(300–600)
HIV status:not checked
5 8 mo/F Fever and
seizures
Immunoglobulins
IgG:13.54(6.5–16)
IgA: 0.19 (0.4–3.5)
IgM: 2.8(0.5–3)
IgE: not done
Flow Cytometry
CD3:1624(2800–3500)
CD4: 592(1700–2400)
CD8: 831(800–1100).
CD19: 425(1000–1700)
CD56: 913(300–800)
HIV status: not checked
No No Known
candidate gene
for PID
identified
4.5 mo. 6 mo. Alive
6 11 mo/M Recurrent
diarrhea and
pneumonia
Immunoglobulins
IgG:4.96((6.5–16))
IgM:0.09(0.5–3)
IgA: 0.16(0.4–3.5)
IgE:1.0(1.4–52.3)
Flow Cytometry
CD3: 244(1800–3300)
CD4: 105(900–2300)
CD8: 146(700–1500)
CD19:1.0(700–1700)
CD56: 89(300–800)
HIV status: Negative
SCID No Known
candidate gene
for PID
identified
4 mo. 11 mo. Alive
No
recurrence of
infections in
follow up.
Less likely to
be a PID
7 5.5 mo/M Recurrent
pneumonia,
skin rash and
hyperglycemia
Immunoglobulins
IgG:0.26(6.5–16)
IgA: 0.09(0.4–3.5)
IgM:0.12(0.5–3)
IgE:5.96 (1.4–52.3)
Flow cytometry
CD3: 2244(1800–3300)
CD4: 879 (900–2300)
CD8: 1167(700–1500)
CD56:196 (300–800)
CD19: 21 (700–1700)
HIV status: not checked
Early onset
diabetes and
Agamma
globulinemia
STAT3 GOF?
LRBA?
No Known
candidate gene
for PID
identified
2 mo. 5 mo. Alive
Recurrent
otitis media,
eczematous
skin rash and
failure to
thrive
Table 2. Clinical and laboratory characteristics of suspected primary immunodeficiency patients with No known gene mutation for PID. a. CD count unit: cells/mm3,Immunoglobulin unit: G/L, IgE unit:
IU/ml
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crucial in aiding and establishing the diagnosis of
suspected PIDs in these countries.9
Patients with PIDs are often diagnosed based on
a clinical history of recurrent infections due to
atypical or less virulent pathogens.16 However,
they can also present with non-infectious mani-
festations, such as autoimmune disease, or albi-
nism.17 Verma et al published a case series of 27
PID cases in whom recurrent pneumonia and
recurrent diarrhea were the most common
presentations. In our case series, recurrent
diarrhea was the most common clinical
presentation followed by recurrent pneumonia,
oral thrush, skin rash, and abscesses.18
Live vaccines (eg, BCG, OPV) should not be
administered to children with PIDs due to the risk
of developing mycobacterial disease with the ba-
cillus CalmetteGuérin (BCG) vaccine or Vaccine
Derived Poliovirus (VDP) with the oral polio virus
vaccine (OPV).19 Shahmohammadi S et al
reviewed 17 cases of disseminated BCG infection
in Iran from 2005 to 2010 and observed that 10
(59%) out of the 17 cases had impaired immunity
due to an incompetent immune system.20 In
Pakistan, these vaccines (BCG and OPV) are a
part of the national immunization programme;
hence, they are administered routinely, much
earlier before a diagnosis of immunodeficiency
can be suspected or established in children. In
our case series, almost all cases were vaccinated
with the BCG and OPV at birth; so far, none of
them have developed any sign of disease due to
the vaccination (VDP or Tuberculosis). Although
this report is based on a limited number of cases,
it does raise the need for a newborn screening
program in the long term, so that children
suspected of having a PID do not receive a live
vaccine at birth.
Early recognition and prompt diagnosis of PIDs
help in preventing significant disease related
morbidity and mortality. A clinical history and
physical examination together with supportive
laboratory investigations can provide clues about
an underlying PID. Nevertheless, molecular testing
plays an essential role in not only confirming the
diagnosis but also in identifying the exact nature of
the defect. It also assists in patient care as it allows
for prognostic counseling.21
Varying degree of support for diagnosing PIDs
is available from different institutions and philan-
thropic foundations such as the (International
Union of Immunological Sciences (IUIS), European
Society for Immunodeficiencies (ESID), Immune
Deficiency Foundation (IDF), and Jeffrey Modell
Foundation JMF). In most LMICs, diagnostic and
therapeutic services are sparse and/or inacces-
sible. Armed Forces Institute of Pathology (AFIP) in
Rawalpindi, Pakistan is a center where limited im-
mune diagnostics are available but molecular
techniques are still lacking. Furthermore, this is the
only center where some form of diagnostics is
available for PIDs. For a country with a population
Fig. 1 Study flow showing distribution of study subjects
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of 200 million and a birth rate of 29.8 births per
1,000 people, a single facility is not enough to
meet the demands.
To our knowledge, this is the first report of PID
cases from Pakistan confirmed with molecular
diagnosis. The cases reported here only reflect
cases referred to a large tertiary care center and
represent only the tip of the iceberg.
As a next step, we plan to set up a national
registry to bring together individual efforts so that
medical care for affected individuals can be
improved. Having a national registry will facilitate
exchange of experience in the diagnosis and
management of PIDs with international registries
and will help push policies for support of children
with an identified PID. We plan to work towards
achieving philanthropic support for IVIG/SCIG or
bone marrow transplant (BMT) for the treatment of
diagnosed patients. Hopefully, these collective ef-
forts will help with early identification of PIDs, aid
in tracking and establishing epidemiological data
of PIDs in Pakistan, and help decrease the mortality
of patients in developing countries around the
world.
CONCLUSION
PIDs are not uncommon in Pakistan; their diag-
nosis may be missed or delayed due to the over-
lapping of clinical features of PIDs with other
diseases and a lack of diagnostic facilities. There is
a need to increase testing capacity for early
recognition, diagnosis and management of PIDs to
decrease morbidity and mortality. There is also a
need to establish a national registry for estimating
the true burden of PIDs in the country to aid in
policy recommendations.
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